Ask AI

Accelerating LDL-C Control: Overcoming Clinical Inertia in the Age of Potent PCSK9 Inhibition

Deepen your understanding of the causal role elevated LDL-C plays in dyslipidemia progression and atherosclerotic cardiovascular disease risk as well as the latest evidence supporting PCSK9 inhibition to achieve individualized goals and optimize outcomes, through expert-written ClinicalThought commentaries, downloadable slides, and an on-demand webcast.

Share

Program Content

Activities

Timely LDL C Treatment Intensification
Closing Gaps in LDL-C Control: Treatment Intensification and Emerging PCSK9 Options
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 30, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

Supporters

This activity is supported by educational funding provided by Amgen and Novartis Pharmaceuticals Corporation.

Amgen

Novartis Pharmaceuticals Corporation